C反应蛋白与前列腺癌经内分泌药物治疗期间关系的研究进展
Research Progress on the Relationship between C-Reactive Protein and Prostate Cancer during Endocrine Drug Therapy
DOI: 10.12677/ACM.2022.12101381, PDF,   
作者: 吴克爽：青海大学，青海 西宁；任海林：青海大学附属医院，青海 西宁
关键词: 前列腺癌；内分泌治疗；C反应蛋白；预后；Prostate Cancer； Endocrinoe Therapy； C-Reactive Protein； Prognosis
摘要: 近些年来，由于生活的改变，工作寿命的拉长，人体癌症的发病率也相应增加。越来越多的研究已经证实炎症因子对恶性肿瘤的发生发展起到了确定性作用。包括泌尿系统肿瘤。C反应蛋白是一种急性期反应物，被认为是急性和慢性全身炎症的标志物，且易于测量。本章将对炎症因子中最主要的C反应蛋白和泌尿系统肿瘤中前列腺癌的发展相关的最新进展作一简要综述。
Abstract: In recent years, due to changes in life and longer working life, the incidence of cancer in the human body has increased accordingly. More and more studies have confirmed that inflammatory factors play a deterministic role in the occurrence and development of malignant tumors, which include tumors of the urinary system. C-reactive protein, an acute phase reactant, is considered to be a marker of acute and chronic systemic inflammation and is easy to measure. In this chapter, we will briefly review the recent progress of C-reactive protein, the most important inflammatory factor, and the development of prostate cancer in urinary tumors.
文章引用：吴克爽, 任海林. C反应蛋白与前列腺癌经内分泌药物治疗期间关系的研究进展[J]. 临床医学进展, 2022, 12(10): 9551-9556. https://doi.org/10.12677/ACM.2022.12101381

参考文献

[1] Torre, L.A., Siegel, R.L., Ward, E.M. and Jemal, A. (2016) Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer Epidemiology, Biomarkers & Prevention, 25, 16-27. [Google Scholar] [CrossRef] 
[2] Litwin, M.S. and Tan, H.J. (2017) The Diagnosis and Treat-ment of Prostate Cancer: A Review. JAMA, 317, 2532-2542. [Google Scholar] [CrossRef] [PubMed]
[3] 尤祥云, 孙德明, 喻俊峰, 易成, 向振东. 前列腺癌双极雄激素治疗的研究进展[J]. 临床泌尿外科杂志, 2021, 36(12): 989-992.
[4] 罗伟, 吴静, 方克伟. C-反应蛋白与前列腺癌相关性的研究进展[J]. 东南国防医药, 2020, 22(5): 516-520.
[5] Lilja, H. (2008) Testing New PSA Subforms to Enhance the Accuracy of Predicting Cancer Risk and Disease Outcome in Prostate Cancer. Clinical Chemistry, 54, 1248-1249. [Google Scholar] [CrossRef] [PubMed]
[6] Lilja, H., Ulmert, D. and Vickers, A.J. (2008) Prostate-Specific Antigen and Prostate Cancer: Prediction, Detection and Monitoring. Nature Reviews Cancer, 8, 268-278. [Google Scholar] [CrossRef] [PubMed]
[7] Cary, K.C. and Cooperberg, M.R. (2013) Biomarkers in Prostate Cancer Surveillance and Screening: Past, Present, and Future. Therapeutic Advances in Urology, 5, 318-329. [Google Scholar] [CrossRef] [PubMed]
[8] 文锐, 马可为, 黄翔华, 乔建坤, 云志中. 前列腺癌早期诊断相关生物标志物的研究进展[J]. 内蒙古医学杂志, 2022, 54(7): 821-824+828.
[9] Saini, S. (2016) PSA and Be-yond: Alternative Prostate Cancer Biomarkers. Cellular Oncology, 39, 97-106. [Google Scholar] [CrossRef] [PubMed]
[10] Hart, P.C., Rajab, I.M., Alebraheem, M. and Potempa, L.A. (2020) C-Reactive Protein and Cancer-Diagnostic and Therapeutic Insights. Frontiers in Immunology, 11, Article ID: 595835. [Google Scholar] [CrossRef] [PubMed]
[11] Stikbakke, E., Richardsen, E., Knutsen, T., Wilsgaard, T., Gio-vannucci, E.L., McTiernan, A., Eggen, A.E., Haugnes, H.S. and Thune, I. (2020) Inflammatory Serum Markers and Risk and Severity of Prostate Cancer: The PROCA-Life Study. International Journal of Cancer, 147, 84-92. [Google Scholar] [CrossRef] [PubMed]
[12] De Nunzio, C., Kramer, G., Marberger, M., Montironi, R., Nelson, W., Schröder, F., Sciarra, A. and Tubaro, A. (2011) The Controversial Relationship between Benign Prostatic Hyperplasia and Prostate Cancer: The Role of Inflammation. European Urology, 60, 106-117. [Google Scholar] [CrossRef] [PubMed]
[13] Sciarra, A., Gentilucci, A., Salciccia, S., Pierella, F., Del Bianco, F., Gentile, V., Silvestri, I. and Cattarino, S. (2016) Prognostic Value of Inflammation in Prostate Cancer Progression and Response to Therapeutic: A Critical Review. Journal of Inflammation, 13, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
[14] Ablij, H. and Meinders, A. (2002) C-Reactive Protein: History and Revival. European Journal of Internal Medicine, 13, 412-422. [Google Scholar] [CrossRef] 
[15] Moutachakkir, M., Lamrani Hanchi, A., Baraou, A., Bou-khira, A. and Chellak, S. (2017) Immunoanalytical Characteristics of C-Reactive Protein and High Sensitivity C-Reactive Protein. Annales de Biologie Clinique, 75, 225-229. [Google Scholar] [CrossRef] [PubMed]
[16] Sevcenco, S., Mathieu, R., Baltzer, P., Klatte, T., Fajkovic, H., Seitz, C., Karakiewicz, P.I., Rouprêt, M., Rink, M., Kluth, L., Trinh, Q.D., Loidl, W., Briganti, A., Scherr, D.S. and Shariat, S.F. (2016) The Prognostic Role of Preoperative Serum C-Reactive Protein in Predicting the Biochemical Recurrence in Pa-tients Treated with Radical Prostatectomy. Prostate Cancer and Prostatic Diseases, 19, 163-167. [Google Scholar] [CrossRef] [PubMed]
[17] Hall, W.A., Nickleach, D.C., Master, V.A., Prabhu, R.S., Rossi, P.J., Godette, K., Cooper, S. and Jani, A.B. (2013) The Association between C-Reactive Protein (CRP) Level and Biochemical Failure-Free Survival in Patients after Radiation Therapy for Nonmetastatic Adenocarcinoma of the Prostate. Cancer, 119, 3272-3279. [Google Scholar] [CrossRef] [PubMed]
[18] Van Hemelrijck, M., Jungner, I., Walldius, G., Garmo, H., Binda, E., Hayday, A., Lambe, M., Holmberg, L. and Hammar, N. (2011) Risk of Prostate Cancer Is Not Associated with Levels of C-Reactive Protein and Other Commonly Used Markers of Inflammation. International Journal of Cancer, 129, 1485-1492. [Google Scholar] [CrossRef] [PubMed]
[19] Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B.Y.,Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., De Porre, P., Kheoh, T., Park, Y.C., Todd, M.B., Chi, K.N. and LATITUDE Investigators (2017) Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine, 377, 352-360. [Google Scholar] [CrossRef] 
[20] Davis, I.D., Martin, A.J., Stockler, M.R., Begbie, S., Chi, K.N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W.E., Horvath, L.G., Joshua, A.M., Lawrence, N.J., Marx, G., McCaffrey, J., McDermott, R., McJannett, M., North, S.A., Parnis, F., Parulekar, W., Pook, D.W., Reaume, M.N., Sandhu, S.K., Tan, A., Tan, T.H., Thomson, A., Tu, E., Vera-Badillo, F., Williams, S.G., Yip, S., Zhang, A.Y., Zielinski, R.R., Sweeney, C.J. and ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (2019) Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 381, 121-131. [Google Scholar] [CrossRef] 
[21] Fizazi, K., Shore, N., Tammela, T.L., Ulys, A., Vjaters, E., Polya-kov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Kappeler, C., Snapir, A., Sarapohja, T., Smith, M.R. and ARAMIS Investigators (2019) Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine, 380, 1235-1246. [Google Scholar] [CrossRef] 
[22] O’Brian, D., Prunty, M., Hill, A. and Shoag, J. (2021) The Role of C-Reactive Protein in Kidney, Bladder, and Prostate Cancers. Frontiers in Immunology, 12, Article ID: 721989. [Google Scholar] [CrossRef] [PubMed]
[23] 胡志全, 甘家骅, 田继华. 转移性前列腺癌新型内分泌药物治疗进展[J]. 中华泌尿外科杂志, 2021, 42(Z2): 3-6.
[24] McArdle, P.A., Mir, K., Almushatat, A.S., Wallace, A.M., Underwood, M.A. and McMillan, D.C. (2006) Systemic Inflammatory Response, Prostate-Specific Antigen and Survival in Patients with Metastatic Prostate Cancer. Urologia Internationalis, 77, 127-129. [Google Scholar] [CrossRef] [PubMed]
[25] Nakashima, J., Kikuchi, E., Miyajima, A., Nakagawa, K., Oya, M., Ohi-gashi, T. and Murai, M. (2008) Simple Stratification of Survival Using Bone Scan and Serum C-Reactive Protein in Prostate Cancer Patients with Metastases. Urologia Internationalis, 80, 129-133. [Google Scholar] [CrossRef] [PubMed]
[26] Liu, Y., Chen, J.Q., Xie, L., Wang, J., Li, T., He, Y., Gao, Y., Qin, X. and Li, S. (2014) Effect of Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs on Prostate Cancer Incidence and Mortality: A Systematic Review and Meta-Analysis. BMC Medicine, 12, Article No. 55. [Google Scholar] [CrossRef] [PubMed]

为你推荐